Leukemias | Clinical

Ponatinib/Blinatumomab Combo Shows Promising Efficacy and Safety in Ph+ ALL

January 20, 2023

Phase 2 study shows ponatinib and blinatumomab to represent a promising chemotherapy-free, hematopoietic stem cell transplant–sparing treatment for patients with Philadelphia chromosome–positive acute lymphocytic leukemia.

Study of Ponatinib Versus Imatinib Meets Primary End Point in Ph+ ALL

November 30, 2022

Takeda Pharmaceuticals announced that the phase 3 PhALLCON trial of ponatinib for Philadelphia-positive acute lymphoblastic leukemia succeeded in improving the rate of minimal residual disease–negative complete remission.